In summary, our data make sense in light of five recent studies [26]–[30], which demonstrated that KRAS codon 13 mutations, but not codon 12 mutations, conferred benefit from cetuximab therapy in advanced colorectal cancer. Here, KRAS is linked to colorectal cancer.